Thermo Fisher Scientific Stock News

Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.

MUNICH--(BUSINESS WIRE)--Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology pla...

Thermo Fisher Scientific plans to sell its diagnostics unit for about $4 billion in an attempt to offload some of its low-growth assets, the Financial Times reported on Thursday, citing people familiar with the matter.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) to help push the boundaries of scientific discovery. Delivering unrivaled analytical performance and speed, the...

The neutral DCF model implemented in this article suggests that Thermo Fisher is undervalued by 29.24%. Thermo Fisher has invested, on average, 16.51% of its revenues in capex between 2019 and 2024. Due to the significant investment in capex, Thermo Fisher's revenues have increased at a 12.95% CAGR between 2019 and 2024.

Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary, not reflective of structural weakness in its fundamentals. The company is mitigating trade impacts by investing $2B in US manufacturing, leveraging diversification and innovation, and expects headwinds to peak this year. Biopharma growth, strategic acquisitions, and rapid product innovation position...

Market extremes often drive flawed narratives. Many investors get spooked by sell-offs or seduced by overvaluations, when real opportunity hides in discomfort. While today's market isn't euphoric, it's not cheap either. Risks remain, especially if growth stumbles. Yet long-term valuations may have structurally shifted. That's why I'm laser-focused on deep-value names. In this article, I highlig...

KHC, CVX, and TMO stand out as some of the hardest-hit names held by big-name hedge funds.